ArticleDiscover oncology2025
Prognostic factors and the role of chemotherapy in patients with pT3N0M0 gastric cancer: a propensity score matching analysis based on the SEER database.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of chemotherapy for pT3N0M0 gastric cancer after curative gastrectomy remains controversial. This study aimed to identify prognostic factors and evaluate the influence of chemotherapy on pT3N0M0 GC.
methodsThe pT3N0M0 GC patients diagnosed between 2004 and 2021 were identified in the Surveillance, Epidemiology, and End Results database. They were divided into the chemotherapy group and the non-chemotherapy group. Cox proportional hazard regression analyses, Kaplan-Meier survival analyses, competing risk analyses, and propensity score matching were employed.
resultsA total of 1468 pT3N0M0 GC patients were included in the original cohort and 618 patients (309 in each group) were selected to construct the matched cohort. Age, location, tumor grade, Lauren type, chemotherapy, and number of examined lymph nodes(eLN) were observed to affect the prognosis of patients. Chemotherapy was an independent prognostic factor for pT3N0M0 GC. Survival analyses identified that patients with chemotherapy had a better prognosis than those without chemotherapy in the two cohorts. Competing risk analyses demonstrated that the cumulative incidence of cancer-specific death was significantly lower among patients with chemotherapy than those without chemotherapy. Survival analyses based on subgroups presented that chemotherapy could significantly improve the prognosis of those patients with high-risk prognostic factors, such as age > 65 years, location up, grade low, and diffuse type.
conclusionAge, tumor location, tumor grade, Lauren type, chemotherapy, and number of eLN were associated with the prognosis of pT3N0M0 GC. Patients with pT3N0M0 GC could benefit from chemotherapy. Adjuvant chemotherapy might be recommended for these patients after curative gastrectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.